A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors

Summary

This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety and immunogenicity of HLX18 and OPDIVO® in patients with resected esophageal or gastroesophageal junction cancer (EC/GEJC), melanoma (MEL), or urothelial carcinoma (UC).

Timeline

Start

2026-06-30

Primary completion

2027-08-12

Completion

2028-06-13

Drugs

Indications